Blog / Archives
2010 Life Science Portfolio-Look at Immucor (BLUD)
We are currently rebalancing our 2010 Life Science Portfolio (See under "Articles" at top of WEB site). We are updating our Diagnostics and Genomics Model Portfolio as follows: Our winners for a 14...
Sequenom (SQNM) Catching Bids at $5.75
Sequenom is finding price support today at $5.75, volume of 4.6M at 1p, after a severe three day downdraft triggered by their earnings release. Net loss for Q4 was $18.4M on Revenues of $10.8M....
What’s Next for Helicos(HLCS)?
Helicos made a timely entrance in the race for genetic analysis systems with their HeliScope "true single molecule sequencer" (tSMS), "the first DNA microscope". The technology was positioned as...
Intermune(ITMN) up 60% on Panel Go-Ahead
The FDA Panel of lung experts voted 9-3 in favor of approval of Intermune's drug perfenidone for idiopathic pulmonary fibrosis. The stock was 15 at the end of February(see raygent.com last week) and...
Why Healthcare Reform is So Difficult
There is a simple reason why healthcare reform is so hard to do-there has to be winners and losers. We have had many months of discussion on how to pay for healthcare reform such as cuts in...
Biotech MoJo Risin’ with InterMune Surge
The rally in biotech is back with lots of help from InterMune (ITMN).The stock was up over 60% to 23 this am after the Company posted briefing documents for the March 9 Pulmonary-Allergy Drugs...
Medivation hangover -stock stable
Despite a bunch of way-too-late analyst downgrades (JPMorgan, Roth, Hapoalim) MDVN stock is up 1%+ at $13.25 on volume of 8.8M shares. But there are two interesting articles coming out of the...
Medivation Chills Biotech Sector
Medivation (MDVN) released disappointing Phase III results for its Alzheimer drug, known as dimebon, saying that the drug was ineffective in treating cognitive decline or behavioral disorders. The...
Microfluidics (MFLU.OB) Update-Turnaround intact
Microfluidics announced Year-End 2009 and Q4 results yesterday and delivered numbers pretty much according to plan. Q4 Income was $80k; Gross margin at 60% Achieved $525k EBITA for Full Year;...
Clinical Diagnostics Part 2: market sector poised for growth
The drive to reduce healthcare costs and perform Comparative Effectiveness Research can get support from next generation diagnostic tests. A recent article by Bill Malone in Clinical Laboratory...